Grade 2 gliomas, IDH mutated (with or without the 1p/19q codeletion) considered at high risk because of the age at diagnosis (more than 40 years) or the presence of a residual tumor after surgery: the benefit of the radiotherapy plus the PCV chemotherapy has been reported in a phase 3 randomized clinical trial [28]. The gene discussed is IDH2; the disease is central nervous system cancer.